Gene-Silencing shot aims to quiet hepatitis b for good

NCT ID NCT07200193

Recruiting now Disease control Sponsor: nChroma Bio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new therapy called CRMA-1001, which uses epigenetic gene silencing to turn off the hepatitis B virus in the body. About 66 adults with chronic hepatitis B who are already on antiviral pills will receive one or more IV infusions of the therapy. The main goal is to check safety and tolerability, while also looking at how the body processes the drug and whether it can reduce virus levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CRMA-1001 (epigenetic gene silencing therapy given by IV infusion)
What this could lead to: If successful, this could lead to a new way to control chronic hepatitis B by silencing the virus's genes, potentially reducing or eliminating the need for lifelong daily antiviral pills.
What could go wrong: This is an early phase 1/2 trial with only 66 participants, so safety and effectiveness are not yet proven. The therapy is new and may cause side effects or fail to control the virus long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection Hepatitis, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPAITITIS B

Contacts and locations

Locations

Hospices Civils De Leon
RECRUITING

Lyon, 69002, France
King's College Hospital
RECRUITING

London, SE5 9RS, United Kingdom
New Zealand Clinical Research
RECRUITING

Auckland, New Zealand
Queen Mary Hospital, The University of Hong Kong
RECRUITING

Hong Kong, 999077, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.